Last reviewed · How we verify

trimethoprim-sulfamethoxazole or doxycycline

University of Texas Southwestern Medical Center · Phase 1 active Small molecule Quality 3/100

trimethoprim-sulfamethoxazole or doxycycline is a Small molecule drug developed by University of Texas Southwestern Medical Center. It is currently in Phase 1 development.

At a glance

Generic nametrimethoprim-sulfamethoxazole or doxycycline
SponsorUniversity of Texas Southwestern Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about trimethoprim-sulfamethoxazole or doxycycline

What is trimethoprim-sulfamethoxazole or doxycycline?

trimethoprim-sulfamethoxazole or doxycycline is a Small molecule drug developed by University of Texas Southwestern Medical Center.

Who makes trimethoprim-sulfamethoxazole or doxycycline?

trimethoprim-sulfamethoxazole or doxycycline is developed by University of Texas Southwestern Medical Center (see full University of Texas Southwestern Medical Center pipeline at /company/university-of-texas-southwestern-medical-center).

What development phase is trimethoprim-sulfamethoxazole or doxycycline in?

trimethoprim-sulfamethoxazole or doxycycline is in Phase 1.

Related